Clinical Trials Logo

Amyloid Plaque clinical trials

View clinical trials related to Amyloid Plaque.

Filter by:
  • None
  • Page 1

NCT ID: NCT06177028 Not yet recruiting - Clinical trials for Cognitive Dysfunction

MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

Start date: January 2, 2024
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, parallel group study. The use of placebo is appropriate to minimize bias related to treatment expectations of the subject, study partner, and site investigator, as well as to changes in the relationship between the subject and study partner that might occur with the initiation of treatment and expectation of improvement in motor symptoms or cognition. Changes in subject/study partner interactions can impact subject mood and might introduce biases that cannot be quantified. The double-blind use of placebo will also prevent bias in the clinical and scientific assessments.

NCT ID: NCT05462106 Recruiting - Alzheimer's Disease Clinical Trials

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Start date: June 21, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.

NCT ID: NCT04913454 Not yet recruiting - Alzheimer Disease Clinical Trials

CLearing Alzheimer's Disease Molecular Pathology Without Medications

CLAMP
Start date: August 1, 2021
Phase: N/A
Study type: Interventional

According to the most popular pathophysiological models of Alzheimer's disease, the amyloid hypothesis, amyloid deposition is the causative event triggering a chain of other downstream events which finally lead to Alzheimer's disease and dementia. In mouse models of Alzheimer's disease, 40 Hz multi-sensory (auditory and visual) stimulation was able to reduce the number and size of amyloid plaques throughout cortex and improve cognitive performance. The primary objective of this study is to assess whether an intervention consisting of 40 Hz multi-sensory (auditory and visual) stimulation is able to reduce the amyloid load in non-demented amyloid-positive individuals. As secondary objectives, the investigators will assess whether such intervention is able to: - improve the brain electrical activity, - improve or slow down the worsening of Alzheimer's blood-based biomarkers, - improve or slow down the worsening of cognition.

NCT ID: NCT04032626 Recruiting - Clinical trials for Cognitive Dysfunction

MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients

MCLENA-1
Start date: July 22, 2020
Phase: Phase 2
Study type: Interventional

Accumulating evidence indicates that inflammation is prominent both in the blood and central nervous system (CNS) of Alzheimer's disease (AD) patients. These data suggest that systemic inflammation plays a crucial role in the cause and effects of AD neuropathology. Capitalizing on the experience from a previous clinical trial with thalidomide, here, the investigators hypothesize that modulating both systemic and CNS inflammation via the pleiotropic immunomodulator lenalidomide is a putative therapeutic intervention for AD if administered at a proper time window during the course of the disease.